BACKGROUND AND OBJECTIVES: The increasing number of podocyte-expressed genes implicated in steroid-resistant nephrotic syndrome (SRNS), the phenotypic variability, and the uncharacterized relative frequency of mutations in these genes in pediatric and adult patients with SRNS complicate their routine genetic analysis. Our aim was to compile the clinical and genetic data of eight podocyte genes analyzed in 110 cases (125 patients) with SRNS (ranging from congenital to adult onset) to provide a genetic testing approach. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Mutation analysis was performed by sequencing the NPHS1, NPHS2, TRPC6, CD2AP, PLCE1, INF2, WT1 (exons 8 and 9), and ACTN4 (exons 1 to 10) genes. RESULTS: We identified causing mutations in 34% (37/110) of SRNS patients, representing 67% (16/24) familial and 25% (21/86) sporadic cases. Mutations were detected in 100% of congenital-onset, 57% of infantile-onset, 24 and 36% of early and late childhood-onset, 25% of adolescent-onset, and 14% of adult-onset patients. The most frequently mutated gene was NPHS1 in congenital onset and NPHS2 in the other groups. A partial remission was observed in 7 of 26 mutation carriers treated with immunosuppressive agents and/or angiotensin-converting enzyme inhibitors. Patients with NPHS1 mutations showed a faster progression to ESRD than patients with NPHS2 mutations. None of these mutation carriers relapsed after kidney transplantation. CONCLUSIONS: We propose a genetic testing algorithm for SRNS based on the age at onset and the familial/sporadic status. Mutation analysis of specific podocyte-genes has a clinical value in all age groups, especially in children.
BACKGROUND AND OBJECTIVES: The increasing number of podocyte-expressed genes implicated in steroid-resistant nephrotic syndrome (SRNS), the phenotypic variability, and the uncharacterized relative frequency of mutations in these genes in pediatric and adult patients with SRNS complicate their routine genetic analysis. Our aim was to compile the clinical and genetic data of eight podocyte genes analyzed in 110 cases (125 patients) with SRNS (ranging from congenital to adult onset) to provide a genetic testing approach. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Mutation analysis was performed by sequencing the NPHS1, NPHS2, TRPC6, CD2AP, PLCE1, INF2, WT1 (exons 8 and 9), and ACTN4 (exons 1 to 10) genes. RESULTS: We identified causing mutations in 34% (37/110) of SRNS patients, representing 67% (16/24) familial and 25% (21/86) sporadic cases. Mutations were detected in 100% of congenital-onset, 57% of infantile-onset, 24 and 36% of early and late childhood-onset, 25% of adolescent-onset, and 14% of adult-onset patients. The most frequently mutated gene was NPHS1 in congenital onset and NPHS2 in the other groups. A partial remission was observed in 7 of 26 mutation carriers treated with immunosuppressive agents and/or angiotensin-converting enzyme inhibitors. Patients with NPHS1 mutations showed a faster progression to ESRD than patients with NPHS2 mutations. None of these mutation carriers relapsed after kidney transplantation. CONCLUSIONS: We propose a genetic testing algorithm for SRNS based on the age at onset and the familial/sporadic status. Mutation analysis of specific podocyte-genes has a clinical value in all age groups, especially in children.
Authors: Rebecca A Barnetson; Nicola Cartwright; Annelot van Vliet; Naila Haq; Kate Drew; Susan Farrington; Nicola Williams; Jon Warner; Harry Campbell; Mary E Porteous; Malcolm G Dunlop Journal: Hum Mutat Date: 2008-03 Impact factor: 4.878
Authors: Marije Löwik; Elena Levtchenko; Dineke Westra; Patricia Groenen; Eric Steenbergen; Jan Weening; Marc Lilien; Leo Monnens; Lambert van den Heuvel Journal: Nephrol Dial Transplant Date: 2008-04-28 Impact factor: 5.992
Authors: Rasheed Gbadegesin; Bernward G Hinkes; Bethan E Hoskins; Christopher N Vlangos; Saskia F Heeringa; Jinhong Liu; Chantal Loirat; Fatih Ozaltin; Seema Hashmi; Francis Ulmer; Roxanna Cleper; Robert Ettenger; Corinne Antignac; Roger C Wiggins; Martin Zenker; Friedhelm Hildebrandt Journal: Nephrol Dial Transplant Date: 2007-12-08 Impact factor: 5.992
Authors: Louise M McKenzie; Sher L Hendrickson; William A Briggs; Richard A Dart; Stephen M Korbet; Michelle H Mokrzycki; Paul L Kimmel; Tejinder S Ahuja; Jeffrey S Berns; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; Monique Cho; Yu C Zhou; Elizabeth Binns-Roemer; Gregory D Kirk; Jeffrey B Kopp; Cheryl A Winkler Journal: J Am Soc Nephrol Date: 2007-10-17 Impact factor: 10.121
Authors: Stephen J Tonna; Alexander Needham; Krishna Polu; Andrea Uscinski; Gerald B Appel; Ronald J Falk; Avi Katz; Salah Al-Waheeb; Bernard S Kaplan; George Jerums; Judy Savige; Jennifer Harmon; Kang Zhang; Gary C Curhan; Martin R Pollak Journal: BMC Nephrol Date: 2008-09-29 Impact factor: 2.388
Authors: Agnieszka Bińczak-Kuleta; Jacek Rubik; Mieczysław Litwin; Małgorzata Ryder; Klaudyna Lewandowska; Olga Taryma-Leśniak; Jeremy S Clark; Ryszard Grenda; Andrzej Ciechanowicz Journal: Bosn J Basic Med Sci Date: 2014-05 Impact factor: 3.363
Authors: Maija Suvanto; Jaakko Patrakka; Timo Jahnukainen; Pia-Maria Sjöström; Matti Nuutinen; Pekka Arikoski; Janne Kataja; Marjo Kestilä; Hannu Jalanko Journal: Clin Exp Nephrol Date: 2016-08-29 Impact factor: 2.801
Authors: Andrea Kerti; Rózsa Csohány; Attila Szabó; Ottó Arkossy; Péter Sallay; Vincent Moriniére; Virginia Vega-Warner; Gábor Nyírő; Orsolya Lakatos; Tamás Szabó; Beata S Lipska; Franz Schaefer; Corinne Antignac; George Reusz; Tivadar Tulassay; Kálmán Tory Journal: Pediatr Nephrol Date: 2012-12-14 Impact factor: 3.714